Alterola Biotech (ABTI)
OTHER OTC:ABTI
US Market
Holding ABTI?
Track your performance easily

Alterola Biotech (ABTI) Income Statement

11 Followers

Alterola Biotech Income Statement

Last quarter (Q ), Alterola Biotech's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Alterola Biotech's net income was $-419.30K. See Alterola Biotech’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 24Mar 23Mar 22Mar 21Sep 20
Total Revenue
----$ 0.00-
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 1.98M$ 2.11M$ 2.03M$ 6.47M$ 309.50K$ 325.48K
Operating Income
$ -1.98M$ -2.11M$ -2.03M$ -6.35M$ -309.50K$ -325.48K
Net Non Operating Interest Income Expense
----$ 0.00-
Other Income Expense
$ 293.71K$ 293.71K---$ -79.00K
Pretax Income
$ -1.02M$ -1.29M$ -1.47M$ -6.47M$ -309.50K$ -250.51K
Tax Provision
--$ -154.52K-$ 0.00$ -85.17K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -2.07M$ -2.37M$ -1.49M$ -6.47M$ -309.50K$ -250.51K
Basic EPS
----$ >-0.01-
Diluted EPS
----$ >-0.01-
Basic Average Shares
----$ 442.36M$ 118.06M
Diluted Average Shares
----$ 754.28M$ 118.06M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 1.98M$ 2.11M$ 2.03M$ 6.47M$ 309.50K$ 325.48K
Net Income From Continuing And Discontinued Operation
$ -2.07M$ -2.37M$ -2.07M$ -6.47M$ -309.50K$ -250.51K
Normalized Income
$ 133.49K$ -378.86K--$ -309.50K-
Interest Expense
----$ 0.00-
EBIT
$ -4.28M$ -2.37M$ -2.07M$ -6.47M$ -309.50K$ -250.51K
EBITDA
$ -4.28M$ -2.37M$ -2.07M$ -6.47M$ -309.50K$ -250.51K
Currency in USD

Alterola Biotech Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis